Julian Gonsalves explains how public-private partnerships can provide government officials with solutions to meet reliability, resiliency and environmental targets.
Can public-private partnerships (P3s) help governments adapt to the evolving energy landscape?
The energy landscape has been changing dramatically. Aggressive climate goals, impact of COVID-19 on government revenue and budgets, aging infrastructure, decreasing cost of energy, stakeholder pressure, need for resiliency, and innovative technical and market solutions are just a few of the factors driving this transformation.
By: David S. Blaisdell, Senior Manager, Bechtel Enterprises (BEn)
In the past 10-15 years, public agencies have increasingly partnered with the private sector to build and run major new transportation projects, typically through what is commonly known as Public-Private Partnerships, or P3s. In a P3, private-sector partners, either a single company or more often a consortium, are selected through a competitive procurement process to design, build, finance, operate, and maintain (DBFOM) the infrastructure, typically for the construction period plus an operating period of 25 years or longer. The private sector also invests equity and raises financing.
The Pfizer Foundation* announced today 20 grants to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to infectious diseases, including the increasing threat of antimicrobial resistance (AMR), in some of the world’s most vulnerable communities. Recipients of the one-year Global Health Innovation Grants (GHIG) include partners in 12 low- and middle-income countries that will each receive US $100,000, for a total investment this year of US $2 million by The Pfizer Foundation.
by Leah Thibault, CEI Capital Management and Brett Richardson, Coastal Enterprises, Inc.
The idea of “nose-to-tail” dining, shorthand for using as much of an animal as possible, has no field-grown counterpart. What about the grains that make up so much of our agricultural production and diet? Where is our “seed to stalk?”
Antibiotics are a key component in the global effort to eliminate trachoma, the world’s leading infectious cause of blindness. One of several neglected tropical diseases (NTDs) the World Health Organization (WHO) has identified for elimination, trachoma is a preventable disease, and one that affects those living in communities with limited access to healthcare, clean water and sanitation.
Neglected tropical diseases (NTDs) affect over one billion people worldwide. This group of viral, bacterial and parasitic diseases can be found in 149 countries – that’s 76 percent of countries in the world – and most often affects impoverished populations, who lack access to clean water or sanitation and live in close contact with infectious vectors. The effects of NTDs on communities can be devastating – keeping children out of school and preventing adults from going to work or caring for themselves or their families.
Pfizer has long been a partner in the global effort to eliminate trachoma, the world’s leading infectious cause of blindness, through its donation of an oral antibiotic that can help treat and prevent the debilitating disease. Now, Pfizer has announced that it will extend its donation of the antibiotic through 2025, building on the company’s 20-year support of a partnership to eliminate this disease.
By increasing access to these integrated services, we’re helping women access reproductive and sexual health services at the same time their children are vaccinated – and in turn, supporting efforts to improve the health of women and their families by: